TSHA - CIK 0001806310
The table below shows Taysha Gene Therapies, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $319.77M | $139.04M | $143.94M | $87.88M | $149.10M | $251.25M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $324.65M |
| $142.13M |
| $149.87M |
| $96.42M |
| $159.60M |
| $257.88M |
| Property, plant & equipment | $6.74M | $7.49M | $10.83M | $14.96M | $50.61M | $287.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $343.32M | $160.36M | $172.73M | $126.28M | $213.96M | $258.88M |
| Accounts payable | $6.28M | $3.59M | $6.37M | $10.95M | $21.76M | $1.99M |
| Total current liabilities | $26.55M | $26.23M | $36.76M | $62.79M | $51.75M | $7.13M |
| Long-term debt | $50.11M | $43.94M | $40.51M | $37.97M | $37.19M | - |
| Total liabilities | $96.38M | $88.84M | $97.79M | $125.33M | $118.57M | $7.58M |
| Retained earnings | -$711.30M | -$602.30M | -$513.01M | -$401.44M | -$235.65M | -$61.13M |
| Total equity | $246.94M | $71.53M | $74.94M | $949.00K | $95.38M | $251.30M |